Representatives across 12 disease groups make up a council that sets clinical recommendations for oncology care and those decisions are being pushed out in the electronic medical record for decision support at the point of care, said Jeffrey Patton, MD, CEO, OneOncology, and executive chairman of the board, Tennessee Oncology. Patton will lead off OneOncology's Physician Leadership Conference, which runs November 11-13 in Nashville.
Representatives across 12 disease groups make up a council that sets clinical recommendations for oncology care and those decisions are being pushed out in the electronic medical record for decision support at the point of care, said Jeffrey Patton, MD, CEO, OneOncology, and executive chairman of the board, Tennessee Oncology. Patton will lead off OneOncology's Physician Leadership Conference, which runs November 11-13 in Nashville.
Transcript
What is the role of disease groups in the OneOncology clinical pathways program? How do member practices of OneOncology work with these clinical pathways day to day?
At OneOncology, we have a clinical leadership forum called One Council—everything's “one” with us. One Council is really a Senate-based model where we have representatives from each practice make clinical decisions and clinical recommendations. Within that group, we have 12 disease groups, where we have thought leaders or folks interested in specific disease discuss and set our standard of care in those disease groups. And then we're developing a pathway to tool with Flatiron Health and called Flatiron Assist, where those recommendations are written into the electronic medical record, so you don't have to go outside of the electronic medical record to get that decision support tool. And it really is decision support at the point of care.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More